Luca Pierelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3216609/publications.pdf

Version: 2024-02-01

179	4,743	94433 37	123424 61
papers	citations	h-index	g-index

180	180	180	6223
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predictors of cord blood unit cell content in a volume unrestricted large series collections: a chance for a fast and cheap multiparameter selection model. Stem Cell Research and Therapy, 2022, 13, .	5.5	1
2	Two new RHD alleles with deletions spanning multiple exons. Transfusion, 2021, 61, 682-686.	1.6	1
3	Chemotherapy-based versus chemotherapy-free stem cell mobilization (Â± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. Bone Marrow Transplantation, 2021, 56, 1876-1887.	2.4	8
4	International Forum on Transfusion Practices in Haematopoietic Stemâ€Cell Transplantation: Responses. Vox Sanguinis, 2021, 116, e25-e43.	1.5	0
5	International Forum on Transfusion Practices in Haematopoietic Stemâ€Cell Transplantation: Summary. Vox Sanguinis, 2021, 116, 609-612.	1.5	1
6	Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. International Journal of Infectious Diseases, 2021, 106, 338-347.	3.3	43
7	Pain control and functional improvement in patients treated by autologous conditioned serum after failure of platelet rich plasma treatments in knee osteoarthritis. Transfusion Medicine, 2021, 31, 357-364.	1.1	3
8	Vox Sanguinis International forum on the selection and preparation of blood components for intrauterine transfusion. Vox Sanguinis, 2020, 115, e18-e38.	1.5	3
9	The Potential Role of Quorum Sensing in Clonal Growth and Subsequent Expansion of Bone Marrow Stromal Cell Strains in Culture. Stem Cells International, 2019, 2019, 1-10.	2.5	1
10	Human Sinusoidal Subendothelial Cells Regulate Homing and Invasion of Circulating Metastatic Prostate Cancer Cells to Bone Marrow. Cancers, 2019, 11, 763.	3.7	13
11	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. International Journal of Molecular Sciences, 2019, 20, 1903.	4.1	15
12	A proposal for sectorial organizing and quality standards in therapeutic apheresis: The therapeutic apheresis unit (TAU) standards. Journal of Clinical Apheresis, 2019, 34, 513-516.	1.3	0
13	Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years. Transfusion Medicine, 2019, 29, 197-201.	1.1	21
14	Lenograstim 5 Âµg/kg is not superior to biosimilar filgrastim 10 Âµg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. Transfusion, 2018, 58, 1143-1148.	1.6	4
15	CAR-T cells: the long and winding road to solid tumors. Cell Death and Disease, 2018, 9, 282.	6.3	312
16	Vox Sanguinis International Forum on application of fetal blood grouping. Vox Sanguinis, 2018, 113, e26-e35.	1.5	8
17	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplantation, 2018, 53, 422-430.	2.4	24
18	Vox Sanguinis International Forum on application of fetal blood grouping: summary. Vox Sanguinis, 2018, 113, 198-201.	1.5	10

#	Article	IF	Citations
19	International Forum on <scp>GMP</scp>â€grade human platelet lysate for cell propagation: summary. Vox Sanguinis, 2018, 113, 80-87.	1.5	45
20	International Forum on GMPâ€grade human platelet lysate for cell propagation. Vox Sanguinis, 2018, 113, e1-e25.	1.5	11
21	â€œBest practiceâ€• for extracorporeal photopheresis in acute and chronic graftâ€versusâ€host disease by Societaâ€™ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion, 2018, 58, 217-222.	1.6	7
22	Emergency response of four transfusion centers during the last Chikungunya outbreak in Italy. Transfusion, 2018, 58, 3027-3030.	1.6	9
23	Two novel RHD alleles encoding truncated, nonfunctional D polypeptides. Transfusion, 2018, 58, 2082-2083.	1.6	0
24	The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the High mobility group box protein 1 (HMGB1). International Journal of Cardiology, 2017, 249, 349-356.	1.7	10
25	Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sanguinis, 2017, 112, 680-683.	1.5	3
26	Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use. Vox Sanguinis, 2017, 112, e48-e68.	1.5	5
27	GMP-grade platelet lysate enhances proliferation and migration of tenon fibroblasts. Frontiers in Bioscience - Elite, 2016, 8, 84-99.	1.8	14
28	Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues. Stem Cell Research and Therapy, 2016, 7, 122.	5.5	32
29	Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Human Immunology, 2016, 77, 1239-1247.	2.4	8
30	Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 2016, 48, 1369-1378.	3.3	28
31	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
32	Biosimilar filgrastim (Zarzio^{Â®}) vs. lenograstim (Myelostim^{Â®}) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. Leukemia and Lymphoma, 2016, 57, 489-492.	1.3	8
33	Culture of human cell lines by a pathogen-inactivated human platelet lysate. Cytotechnology, 2016, 68, 1185-1195.	1.6	28
34	A prospective, active haemovigilance study with combined cohort analysis of 19Â175 transfusions of platelet components prepared with amotosalenâ€“<scp>UVA</scp> photochemical treatment. Vox Sanguinis, 2015, 109, 343-352.	1.5	73
35	A new standardized clinicalâ€grade protocol for banking human umbilical cord tissue cells. Transfusion, 2015, 55, 2864-2873.	1.6	15
36	The Potential of GMP-Compliant Platelet Lysate to Induce a Permissive State for Cardiovascular Transdifferentiation in Human Mediastinal Adipose Tissue-Derived Mesenchymal Stem Cells. BioMed Research International, 2015, 2015, 1-10.	1.9	16

#	Article	IF	Citations
37	MGL Receptor and Immunity: When the Ligand Can Make the Difference. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	49
38	Stress, burnout, and job satisfaction in 470 health professionals in 98 apheresis units in <scp>I</scp>taly: A SIdEM collaborative study. Journal of Clinical Apheresis, 2015, 30, 297-304.	1.3	18
39	A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective singleâ€blind randomized controlled trial. Transfusion, 2015, 55, 1644-1654.	1.6	85
40	Optimization of the isolation and expansion method of human mediastinalâ€“adipose tissue derived mesenchymal stem cells with virally inactivated GMP-grade platelet lysate. Cytotechnology, 2015, 67, 165-174.	1.6	30
41	Three missense mutations found in theKELgene lead to Kmodor K0red blood cell phenotypes. Transfusion, 2014, 54, 3216-3221.	1.6	8
42	A policy for the disposal of autologous hematopoietic progenitor cells: report from an <scp>I</scp>talian consensus panel. Transfusion, 2014, 54, 2353-2360.	1.6	12
43	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. Cytotherapy, 2014, 16, 101-110.	0.7	6
44	Cytotoxic potential of interleukin-15 stimulated cytokine induced killer (CIK) against epithelial cancer cell lines. Cytotherapy, 2014, 16, S23.	0.7	1
45	Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells. Journal of Translational Medicine, 2014, 12, 28.	4.4	64
46	Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sanguinis, 2014, 106, 197-208.	1.5	86
47	Total nucleated cells as a sole predictor of distinct targets of hematopoietic potential (CD34+ cells) in cord blood units: the results of a large series analysis in autologous cord blood units. Transfusion, 2014, 54, 1256-1262.	1.6	8
48	Central venous catheter insertion in peripheral blood hematopoietic stem cell sibling donors: The SIdEM (Italian Society of Hemapheresis and Cell Manipulation) point of view. Transfusion and Apheresis Science, 2014, 50, 200-206.	1.0	4
49	Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (SocietÃ Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di) Tj ETQq1 1 0.784314 rgBT /Overlo	1.0	7
50	Welcome to the 2nd International Joint Meeting ESFH-SIdEM May 19â€“22, Palazzo dei Congressi, Florence, Italy. Transfusion and Apheresis Science, 2013, 49, 374-375.	1.0	0
51	Extracorporeal photopheresis for the treatment of acute and chronic graftâ€versusâ€host disease in adults and children: best practice recommendations from an <scp>I</scp>talian <scp>S</scp>ociety of <scp>H</scp>emapheresis and <scp>C</scp>ell <scp>M</scp>anipulation (<scp>SIdEM</scp>) and <scp>I</scp>talian <scp>G</scp>roup for <scp>B</scp>one <scp>M</scp>arrow <scp>T</scp>ransplantation (<scp>GITMO</scp>) consensus process. Transfusion, 2013, 53, 2340-2352.	1.6	59
52	Reduction of allogeneic red blood cell usage during cardiac surgery by an integrated intraâ€•and postoperative blood salvage strategy: results of a randomized comparison. Transfusion, 2013, 53, 790-797.	1.6	34
53	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and SocietÃ Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. Transfusion and Apheresis Science, 2013, 49, 615-622.	1.0	8
54	Plerixafor (Mozobil) and other mobilizing agents. Transfusion and Apheresis Science, 2013, 48, 133-135.	1.0	1

#	Article	IF	Citations
55	Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters. American Journal of Clinical Pathology, 2012, 138, 308-309.	0.7	1
56	Survey of current practice for monitoring and management of platelet refractoriness in Italy. Transfusion and Apheresis Science, 2012, 47, 271-276.	1.0	6
57	Poor mobilizer: A retrospective study on proven and predicted incidence according to GITMO criteria. Transfusion and Apheresis Science, 2012, 47, 217-221.	1.0	14
58	Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy, 2012, 14, 841-850.	0.7	24
59	Targeting of macrophage galactoseâ€type <scp>C</scp>â€type lectin (<scp>MGL</scp>) induces <scp>DC</scp> signaling and activation. European Journal of Immunology, 2012, 42, 936-945.	2.9	84
60	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a SocietÃ Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion, 2012, 52, 893-905.	1.6	48
61	Counting of leukocytes in samples from Gâ€CSF mobilized donors, leukapheresis products, and cord blood: the performances of an analyzer with dedicated profiles. International Journal of Laboratory Hematology, 2012, 34, 154-163.	1.3	3
62	Evaluation of haemoglobin, haematocrit, haemolysis, residual protein content and leucocytes in 345 red blood cell concentrates used for the treatment of patients with Î²-thalassaemia. Blood Transfusion, 2012, 10, 39-44.	0.4	12
63	In vitro release and expansion of mesenchymal stem cells by a hyaluronic acid scaffold used in combination with bone marrow. Muscles, Ligaments and Tendons Journal, 2012, 2, 289-94.	0.3	7
64	Integrated strategies for allogeneic blood saving in major elective surgery. Transfusion and Apheresis Science, 2011, 45, 281-285.	1.0	3
65	The application of multiparameter reference intervals for preâ€donation capillary blood counts: the experience of a single institution. Transfusion Medicine, 2011, 21, 344-348.	1.1	0
66	Evaluation of the analytical performances of a portable, 18-parameter hemometric system using capillary blood samples for blood donor enrolment. Vox Sanguinis, 2010, 98, 145-150.	1.5	5
67	Thymoglobulin, interferon-Î³ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. Journal of Translational Medicine, 2010, 8, 129.	4.4	41
68	Cell and Stem-Cell Therapies of Crohnâ€™s Disease and Complications. , 2010, , 131-141.		0
69	Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors. Clinical Cancer Research, 2009, 15, 4299-4311.	7.0	153
70	Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunology, 2009, 10, 46.	2.2	12
71	Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen nonâ€reactive window period and chronic infections. Vox Sanguinis, 2009, 96, 292-297.	1.5	10
72	Interleukin-21 Induces the Differentiation of Human Umbilical Cord Blood CD34. â^'lineageâ^' Cells Into Pseudomature Lytic NK Cells.. Blood, 2009, 114, 1476-1476.	1.4	0

#	Article	IF	Citations
73	A New Method to Evaluate in vitro Myelotoxicity of Antitumour Agents in the First Steps of Drug Development. Basic and Clinical Pharmacology and Toxicology, 2008, 89, 231-236.	0.0	0
74	Expression of CD133-1 and CD133-2 in ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 506-514.	2.5	195
75	Carboplatin-based neoadjuvant treatment with peripheral blood stem cell and growth factor support in locally advanced cervical cancer patients with bulky metastatic lymph nodes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 131, 236-238.	1.1	2
76	Human cord blood CD133+ cells immunoselected by a clinical-grade apparatus differentiate in vitro into endothelial- and cardiomyocyte-like cells. Transfusion, 2007, 47, 280-289.	1.6	48
77	Interleukin (IL)-21 in Combination with IL-15 Induces the Differentiation of Human Umbilical Cord Blood CD34â^'Lineageâ^' Cells into Pseudomature Lytic NK Cells.. Blood, 2007, 110, 4031-4031.	1.4	0
78	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108, 218-227.	1.4	226
79	Accurate prediction of autologous stem cell apheresis yields using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sanguinis, 2006, 91, 126-134.	1.5	32
80	Surfaces of antique marble sculptures in the Uffizi Gallery: reflection of history and image. Surface Engineering, 2005, 21, 378-384.	2.2	3
81	The Intracoelomic Route: A New Approach for in utero Human Cord Blood Stem Cell Transplantation. Fetal Diagnosis and Therapy, 2004, 19, 13-22.	1.4	17
82	Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion, 2004, 44, 1087-1097.	1.6	43
83	Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO. Bone Marrow Transplantation, 2004, 34, 743-744.	2.4	5
84	Granulocyte colonyâ€stimulating factor promotes the generation of regulatory DC through induction of ILâ€10 and IFNâ€Î±. European Journal of Immunology, 2004, 34, 1291-1302.	2.9	120
85	A human umbilical cord stem cell rescue therapy in a murine model of toxic liver injury. Digestive and Liver Disease, 2004, 36, 603-613.	0.9	74
86	Stem cells in gynecology and obstetrics. Panminerva Medica, 2004, 46, 49-59.	0.8	12
87	A Novel Route of Transplantation of Human Cord Blood Stem Cells in Preimmune Fetal Sheep: The Intracelomic Cavity. Stem Cells, 2003, 21, 638-646.	3.2	21
88	Regulated expression of MUC1 epithelial antigen in erythropoiesis. British Journal of Haematology, 2003, 120, 344-352.	2.5	19
89	Evaluation of the human haematopoietic stem cell potential in liver regeneration: Analysis of homing and differentiation patterns in a nod/scid mouse model. Journal of Hepatology, 2003, 38, 80-81.	3.7	0
90	Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy, 2003, 5, 19-30.	0.7	42

#	Article	IF	Citations
91	Identification of a Novel Subpopulation of Human Cord Blood CD34â^'CD133â^'CD7â^'CD45+Lineageâ^'Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15. Journal of Immunology, 2003, 171, 2977-2988.	0.8	42
92	Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clinical Cancer Research, 2003, 9, 195-200.	7.0	24
93	Transforming growth factor-Î²1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia, 2002, 16, 94-105.	7.2	28
94	Survival and Cell Cycle Control in Early Hematopoiesis: Role of Bcl-2, and the Cyclin Dependent Kinase Inhibitors P27 and P21. Leukemia and Lymphoma, 2002, 43, 51-57.	1.3	21
95	Cell Cycle Regulation in Human Hematopoietic Stem Cells: From Isolation to Activation. Leukemia and Lymphoma, 2002, 43, 493-501.	1.3	12
96	Role for granulocyte colonyâ€“stimulating factor in the generation of human T regulatory type 1 cells. Blood, 2002, 100, 2562-2571.	1.4	142
97	Constitutive and Inducible Expression of the Epithelial Antigen MUC1 (CD227) in Human T Cells. Experimental Cell Research, 2002, 280, 107-118.	2.6	27
98	Transforming growth factor-Î²1 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity. British Journal of Haematology, 2002, 118, 627-637.	2.5	19
99	Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplantation, 2002, 30, 571-578.	2.4	13
100	A new blood donation strategy: Automated blood collection (ABC). International Journal of Artificial Organs, 2001, 24, 173-177.	1.4	10
101	Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunology, Immunotherapy, 2001, 49, 641-648.	4.2	19
102	Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. Transfusion, 2001, 41, 674-680.	1.6	11
103	The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion, 2001, 41, 1577-1585.	1.6	12
104	Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biological Procedures Online, 2001, 3, 19-25.	2.9	280
105	CD105 (Endoglin) Expression on Hematopoietic Stem/Progenitor Cells. Leukemia and Lymphoma, 2001, 42, 1195-1206.	1.3	69
106	High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplantation, 2001, 27, 1017-1025.	2.4	14
107	T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors. Experimental Hematology, 2001, 29, 401-415.	0.4	17
108	Immune reconstitution after autologous peripheral blood progenitor cell transplantation. Experimental Hematology, 2001, 29, 1503-1516.	0.4	28

#	Article	IF	Citations
109	Transplantation of Autologous Peripheral Blood Progenitor Cells: Impact of CD34-Cell Selection on Immunological Reconstitution. Leukemia and Lymphoma, 2001, 42, 1207-1220.	1.3	12
110	Flow cytometric analysis of human hemopoietic progenitor differentiation by assessing cell division rate and phenotypic profile. Methods in Cell Biology, 2001, 64, 153-170.	1.1	3
111	Role of DNA-dependent protein kinase in recognition of radiation-induced DNA damage in human peripheral blood mononuclear cells. International Immunology, 2001, 13, 791-797.	4.0	13
112	A New Method to Evaluate in vitro Myelotoxicity of Antitumour Agents in the First Steps of Drug Development. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 231-236.	0.0	7
113	Enhanced Susceptibility to Apoptosis in T Cells Recovering after Autologous Peripheral Blood Progenitor Cell Transplantation: Reversal by Interleukin-15. Cytokines, Cellular & Molecular Therapy, 2000, 6, 189-198.	0.3	3
114	Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. British Journal of Haematology, 2000, 108, 105-115.	2.5	68
115	CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/â^'precursors. British Journal of Haematology, 2000, 108, 610-620.	2.5	43
116	High cyclin-dependent kinase inhibitors in Bcl-2 and Bcl-xL -expressing CD34+ -proliferating haematopoietic progenitors. British Journal of Haematology, 2000, 110, 654-662.	2.5	16
117	Transfected human dendritic cells to induce antitumor immunity. Gene Therapy, 2000, 7, 1458-1466.	4.5	41
118	The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis. Experimental Hematology, 2000, 28, 490-498.	0.4	10
119	Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 519-526.	0.4	37
120	Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Experimental Hematology, 2000, 28, 612-625.	0.4	32
121	Perturbation of lymphocyte mitochondrial function and imbalance between BCL-2 family members as molecular mechanisms for g-csf-induced immune dysfunction. Experimental Hematology, 2000, 28, 112.	0.4	0
122	Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-Î²1 is a cell cycleâ€"independent effect and influences their hematopoietic potential. Blood, 2000, 95, 3001-3009.	1.4	58
123	Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSFâ€"mobilized peripheral blood CD34+ cells. Blood, 2000, 95, 4015-4016.	1.4	20
124	Stem Cell Collection using the Dideco Excel Continuous Flow Blood Cell Separator: Parameters for Optimal Stem Cell Collection Timing. International Journal of Artificial Organs, 2000, 23, 703-709.	1.4	0
125	Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-Î²1 is a cell cycleâ€"independent effect and influences their hematopoietic potential. Blood, 2000, 95, 3001-3009.	1.4	20
126	Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSFâ€"mobilized peripheral blood CD34+ cells. Blood, 2000, 95, 4015-4016.	1.4	6

#	Article	IF	Citations
127	Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. Blood, 2000, 95, 3001-9.	1.4	16
128	Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSF-mobilized peripheral blood CD34+ cells. Blood, 2000, 95, 4015-6.	1.4	6
129	Large Volume Leukapheresis for Collecting Hemopoietic Progenitors: Role of CD 34+ Precount in Predicting Successful Collection. International Journal of Artificial Organs, 1999, 22, 334-341.	1.4	15
130	The Application of Two Different Blood Cell Separators to Harvest CD34+ Cells in Patients Suffering from Non Hodgkin's Lymphoma. International Journal of Artificial Organs, 1999, 22, 583-588.	1.4	3
131	Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer. Annals of Oncology, 1999, 10, 1531-1532.	1.2	2
132	Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison. Journal of Clinical Oncology, 1999, 17, 1288-1288.	1.6	77
133	Effect of age on DNA binding of the ku protein in irradiated human peripheral blood mononuclear cells (PBMC). Experimental Gerontology, 1999, 34, 645-658.	2.8	30
134	Expansion of granulocyte colonyâ€“stimulating factor/chemotherapyâ€“mobilized CD34+ hematopoietic progenitors. Experimental Hematology, 1999, 27, 416-424.	0.4	18
135	Large volume leukapheresis for collecting hemopoietic progenitors: role of CD 34+ precount in predicting successful collection. International Journal of Artificial Organs, 1999, 22, 334-41.	1.4	5
136	In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue. British Journal of Cancer, 1998, 78, 1024-1029.	6.4	21
137	Functional, phenotypic and molecular characterization of cytokine low-responding circulating CD34+ haemopoietic progenitors. British Journal of Haematology, 1998, 102, 1139-1150.	2.5	24
138	Erythroplateletapheresis: A New Strategy in the Global Apheresis Program. International Journal of Artificial Organs, 1998, 21, 17-19.	1.4	2
139	Growth Factor Administration Following Autologous Peripheral Blood Progenitor Cell Transplantation. Leukemia and Lymphoma, 1997, 27, 65-75.	1.3	5
140	Autologous Stem Cell Transplantation: Exogenous Granulocyte Colony-Stimulating Factor or Granulocyte-Macrophage Colony-Stimulating Factor Modulate the Endogenous Cytokine Levels. Blood, 1997, 89, 2615-2617.	1.4	5
141	High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration. British Journal of Cancer, 1997, 75, 1205-1212.	6.4	16
142	Evaluation of Two Different Protocols for Peripheral Blood Stem Cell Collection with the Fresenius AS 104 Blood Cell Separator. Vox Sanguinis, 1997, 73, 230-236.	1.5	16
143	Generation of multinuclear tartrateâ€resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34 + progenitors. British Journal of Haematology, 1997, 96, 64-69.	2.5	17
144	Purified unfractionated Gâ€CSF/chemotherapy mobilized CD34 + peripheral blood progenitors and not bone marrow CD34 + progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. British Journal of Haematology, 1997, 96, 55-63.	2.5	5

#	Article	IF	Citations
145	Autologous stem cell transplantation: evaluation of erythropoietic reconstitution by highly fluorescent reticulocyte counts, erythropoietin, soluble transferrin receptors, ferritin, TIBC and iron dosages. British Journal of Haematology, 1997, 96, 762-775.	2.5	16
146	Evaluation of a new protocol for peripheral blood stem cell collection with the Fresenius AS 104 cell separator. Journal of Clinical Apheresis, 1997, 12, 82-86.	1.3	5
147	The combination of erythropoietin and granulocyte colonyâ€stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. British Journal of Haematology, 1996, 92, 287-294.	2.5	16
148	Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 552-556.	2.9	12
149	Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. European Journal of Cancer, 1995, 31, 1987-1992.	2.8	16
150	Bisdioxopiperazine, (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF 187), Enhances the Antiproliferative Effect of Cisplatin on Human Ovarian Cancer Cells. Gynecologic Oncology, 1995, 57, 16-22.	1.4	3
151	High-dose Chemotherapy with Autologous Peripheral Stem Cell Support in Advanced Ovarian Cancer. Annals of Medicine, 1995, 27, 133-138.	3.8	17
152	Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood, 1994, 84, 3532-3539.	1.4	62
153	Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. American Journal of Hematology, 1994, 46, 18-23.	4.1	12
154	Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study. British Journal of Haematology, 1994, 86, 70-75.	2.5	37
155	Fetal Tissue Collection from Spontaneous Abortions: A Report from a Single Centre. Fetal Diagnosis and Therapy, 1994, 9, 204-208.	1.4	3
156	Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood, 1994, 84, 3532-3539.	1.4	1
157	Characterization of peripheral blood CD34+ progenitor cells mobilized with chemotherapy and granulocyte colony-stimulating factor. Experimental Hematology, 1994, 22, 990-5.	0.4	10
158	In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplantation, 1994, 14, 23-30.	2.4	13
159	Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplantation, 1994, 14, 907-12.	2.4	9
160	Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34Â± haematopoietic progenitor cells. British Journal of Haematology, 1993, 84, 24-30.	2.5	39
161	Evaluation of a Novel Automated Protocol for the Collection of Peripheral Blood Stem Cells Mobilized with Chemotherapy or Chemotherapy Plus G-CSF Using the Fresenius AS104 Cell Separator. Stem Cells and Development, 1993, 2, 145-153.	1.0	17
162	Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. European Journal of Cancer, 1993, 29, 1518-1522.	2.8	22

#	Article	IF	Citations
163	Survival after PBSC Transplantation and Comparison of Engraftment Speed with Autologous and Allogeneic Marrow Transplantation: Results of a Multicenter Study. International Journal of Artificial Organs, 1993, 16, 45-50.	1.4	9
164	Autologous Blood Stem Cell Collection after Chemotherapy in Patients with Sensitive and Refractory Malignancies: A Multicenter Retrospective Study. International Journal of Artificial Organs, 1993, 16, 19-24.	1.4	0
165	In Vitro Expansion of CD34+ Cells Mobilized with Chemotherapy and G-CSF. International Journal of Artificial Organs, 1993, 16, 89-95.	1.4	2
166	Five-year Experience in PBSC Collection: Results of the Catholic University of Rome. International Journal of Artificial Organs, 1993, 16, 39-44.	1.4	4
167	Autologous transplantation of peripheral blood progenitor cells mobilized by chemotherapy with or without G-CSF (filgrastim) in resistant lymphoproliferative diseases: enhanced hemopoietic recovery with filgrastim primed progenitors. Haematologica, 1993, 78, 383-8.	3.5	2
168	Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery. Cancer Research, 1993, 53, 1297-303.	0.9	37
169	Autologous blood stem cell collection after chemotherapy in patients with sensitive and refractory malignancies: a multicenter retrospective study. International Journal of Artificial Organs, 1993, 16 Suppl 5, 19-24.	1.4	0
170	Survival after PBSC transplantation and comparison of engraftment speed with autologous and allogeneic marrow transplantation: results of a multicenter study. International Journal of Artificial Organs, 1993, 16 Suppl 5, 45-50.	1.4	1
171	Autologous Blood Stem Cell Transplantation in Malignant Lymphomas: An Italian Cooperative Study. Leukemia and Lymphoma, 1992, 7, 11-16.	1.3	3
172	Autolo ous blood stem cell transplantation in malignant lymphomas: An itavian cooperative study. International Journal of Cell Cloning, 1992, 10, 132-134.	1.6	5
173	The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leukemia Research, 1992, 16, 497-503.	0.8	49
174	Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. British Journal of Haematology, 1991, 79, 444-450.	2.5	43
175	Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. British Journal of Haematology, 1991, 79, 562-566.	2.5	51
176	Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemotherapy and Pharmacology, 1991, 28, 255-258.	2.3	120
177	Autologous bone marrow processing for autotransplantation using an automated cell processor and a semiautomated procedure. Bone Marrow Transplantation, 1991, 7, 355-61.	2.4	13
178	Effects of natural beta-interferon and recombinant alpha-2B-interferon on proliferation, glucocorticoid receptor content, and antigen expression in cultured HL-60 cells. Cancer, 1990, 65, 920-925.	4.1	15
179	Indicative morphological myelodysplastic alterations of bone marrow in overt AIDS. Haematologica, 1990, 75, 327-33.	3.5	10